AbbVie's (ABBV) Fell in Line with the Broader Biopharmaceutical Industry

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market experienced another period of volatility in the second quarter. As of April 8, the S&P 500 Index had declined more than 11% for the quarter but rebounded swiftly as tariff worries diminished, closing with a gain of 10.9% and reaching new all-time highs. The quarter was led by growth as the Russell 1000 Growth Index outperformed the Russell 1000 Value Index. Momentum and earnings growth were the two most positive factors during the quarter. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.

In its second-quarter 2025 investor letter, Carillon Eagle Growth & Income Fund highlighted stocks such as AbbVie Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company. The one-month return of AbbVie Inc. (NYSE:ABBV) was 8.54%, and its shares gained 5.94% of their value over the last 52 weeks. On August 25, 2025, AbbVie Inc. (NYSE:ABBV) stock closed at $207.55 per share, with a market capitalization of $366.65 billion.

Carillon Eagle Growth & Income Fund stated the following regarding AbbVie Inc. (NYSE:ABBV) in its second quarter 2025 investor letter:

"AbbVie Inc.'s (NYSE:ABBV) shares were a detractor for the portfolio in the second quarter. We attribute the weakness primarily to the underperformance of the broader biopharmaceutical industry, which is under pressure as it navigates policy threats from the Trump administration surrounding both tariffs on the pharmaceutical sector and a proposal to explore most-favored nation prescription drug pricing."

AbbVie Inc. (NYSE:ABBV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 89 hedge fund portfolios held AbbVie Inc. (NYSE:ABBV) at the end of the second quarter, which was 86 in the previous quarter. AbbVie Inc. (NYSE: ABBV) reported total net revenues of $15.4 billion in Q2 2025, exceeding expectations by more than $400 million. While we acknowledge the potential of AbbVie Inc. (NYSE:ABBV) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered AbbVie Inc. (NYSE:ABBV) and shared the list of most undervalued quality stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.